Santiago Foos-Russ

Santiago Foos-Russ

Auto-generated profile, based on publicly available information

Santiago Foos-Russ

Program in Biological Sciences, University of Miami Miller School of Medicine, Miami, Florida

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2026 in Blood Cancer Discovery
Verified
Journal Article
Closed access
ANAustin D. Newsam
Austin D. Newsam
BZBachisio Ziccheddu
Bachisio Ziccheddu
AAAbdessamad Youssfi Alaoui
Abdessamad Youssfi Alaoui
VSVenu Venkatarame Gowda Saralamma
Venu Venkatarame Gowda Saralamma
SFSantiago Foos-Russ
Santiago Foos-Russ
JSJonathan Schatz
Jonathan Schatz
CD19-directed chimeric antigen receptor (CAR-19) T cells are breakthrough therapies for large B-cell lymphomas (LBCL), but fewer than half of patients achieve durable responses. We previously showed that RHOA deletions are enriched in progressing cases, but the role of RHOA deficiency is poorly defined despite its frequent occurrence in newly diagnosed disease. In this study, we show that RHOA loss downregulates CD19, promoting cell-intrinsic resistance to CAR-19 in vitro and in vivo. CD19 decline, however, provides an incomplete explanation of resistance and does not explain high frequency of the deletion in newly diagnosed cases. We therefore performed single-cell assessments of immunocompetent RHOA-deficient lymphoma microenvironments (LME), revealing remarkable concordance with features in CAR-19–resistant patients. Despite increased microenvironmental production of interferon gamma, RHOA-deficient tumor cells themselves show an impaired response to the cytokine, including failed induction of class I MHC molecules. Overall, we describe for the first time how a single-gene alteration recurrent in CAR-19–resistant lymphoma contributes to treatment failures. Significance: RHOA loss of function, which predicts CAR T-cell treatment failure and is present in one in six newly diagnosed LBCL cases, impairs MHC class I display, reprograms LMEs, and downregulates CD19 to promote antigen escape. Del 3p21.31 is therefore a single-gene alteration in LBCL selected for immunotherapy resistance. See related commentary by Perkey and Kline, p. 852

3 November 2026
Verified
Other
Open access
PDF file
ANAustin D. Newsam
Austin D. Newsam
BZBachisio Ziccheddu
Bachisio Ziccheddu
AAAbdessamad Youssfi Alaoui
Abdessamad Youssfi Alaoui
VSVenu Venkatarame Gowda Saralamma
Venu Venkatarame Gowda Saralamma
SFSantiago Foos-Russ
Santiago Foos-Russ
JSJonathan Schatz
Jonathan Schatz
Patient characteristics in the combined data sets.

3 November 2026
Verified
Other
Open access
PDF file
ANAustin D. Newsam
Austin D. Newsam
BZBachisio Ziccheddu
Bachisio Ziccheddu
AAAbdessamad Youssfi Alaoui
Abdessamad Youssfi Alaoui
VSVenu Venkatarame Gowda Saralamma
Venu Venkatarame Gowda Saralamma
SFSantiago Foos-Russ
Santiago Foos-Russ
JSJonathan Schatz
Jonathan Schatz
Characteristics of tumor and CAR-T cells in scRNA-seq data of CAR-T treated mice.

3 November 2026
Verified
Other
Open access
PDF file
ANAustin D. Newsam
Austin D. Newsam
BZBachisio Ziccheddu
Bachisio Ziccheddu
AAAbdessamad Youssfi Alaoui
Abdessamad Youssfi Alaoui
VSVenu Venkatarame Gowda Saralamma
Venu Venkatarame Gowda Saralamma
SFSantiago Foos-Russ
Santiago Foos-Russ
JSJonathan Schatz
Jonathan Schatz
CD19 loss is RHOA-dependent and regulated at the mRNA level.

3 November 2026
Verified
Other
Open access
PDF file
ANAustin D. Newsam
Austin D. Newsam
BZBachisio Ziccheddu
Bachisio Ziccheddu
AAAbdessamad Youssfi Alaoui
Abdessamad Youssfi Alaoui
VSVenu Venkatarame Gowda Saralamma
Venu Venkatarame Gowda Saralamma
SFSantiago Foos-Russ
Santiago Foos-Russ
JSJonathan Schatz
Jonathan Schatz
Phenotypic characterization of RHOA LoF lymphoma cell lines.

3 November 2026
Verified
Other
Open access
ANAustin D. Newsam
Austin D. Newsam
BZBachisio Ziccheddu
Bachisio Ziccheddu
AAAbdessamad Youssfi Alaoui
Abdessamad Youssfi Alaoui
VSVenu Venkatarame Gowda Saralamma
Venu Venkatarame Gowda Saralamma
SFSantiago Foos-Russ
Santiago Foos-Russ
JSJonathan Schatz
Jonathan Schatz
Supplementary Table 1 from RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR T–Resistant Large B-cell Lymphomas